To further investigate the association between HDAC8 and p38 MAPK in cardiac hypertrophy, H9c2 cells were transfected with the pCMV6-HDAC8-HA-Myc plasmid and treated with p38 MAPK inhibitor SB203058 (1 μM; this concentration of SB203058 did not affect cell viability (Figure 7A). Here, MYC is linked to cardiac hypertrophy.